studies up to 40% of renal transplant recipients. Such adverse events can extend along the entire GI tract, and can vary in severity from those which are mild (nausea, discomfort, appetite loss) and do not require altering immunosuppressive regimen to those which are more severe or even life threatening (severe diarrhea, GI tract ulcerations, hemorrhage and perforations).

The etiology of GI disorders following transplantation is not well understood. Because of enterocyte dependency for de novo purine synthesis MMF exposure could thus restrict the ability of intestinal epithelial cells to maintain normal barrier function, or decrease their capacity to recover from damage.

Our patient has experienced a life threatening, severe lower GI bleeding which reoccurred within 2 days upon initial stabilization while on a stable immunosuppressive regimen. Upon dose reduction, the bleeding had stopped, indicating the possible adverse effect of MMF.

A database from the United States Food and Drug Administration’s (US FDA) Adverse Event Reporting System (AERS), containing more than 4,000,000 adverse events reported between 2004 and 2011, has a record of 9 cases of haematochezia (0.02%) associated with MMF treatment (www.drugcite.com; accessed Feb 1, 2012).

We have reported this case to the Croatian National Drug Agency and in feedback letter have been informed that it is a serious, unexpected adverse drug reaction, possibly associated with MMF treatment. A total of 16 cases have been reported to the WHO Adverse Drug Reaction Monitoring Center with two fatal outcomes (WHO, UMC VigiBase, 29th November 2011).

Clinicians should be aware of possible, rare, but life threatening, lower GI bleeding associated with MMF treatment in renal transplant patients. Special caution should be given to patients with digestive system disease even if asymptomatic.

Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.


Dear Editor,
Imerslund-Grasbeck syndrome (IGS) is a rare autosomal recessive disorder characterized by megaloblastic anemia due to selective vitamin B<sub>12</sub> malabsorption and asymptomatic proteinuria. IGS occurs in the first 1-2 years of the life and megaloblastic anemia is responsive to parenteral vitamin B<sub>12</sub> treatment. It is thought that proteinuria is benign in IGS; however, there is no sufficient number of follow-up series in IGS.

Case report
A 22-year-old woman had been referred to our pediatric outpatient clinic with the complaints of pale skin, loss of appetite, ataxia and diarrhea constipation periods when she was 2-year-old. The clinical examination and laboratory studies revealed pallor of conjunctiva, megaloblastic anemia with vitamin B12 deficiency (serum vitamin B<sub>12</sub> level <150pg/ml, hemoglobin: 6.5g/dl, MCV: 104fl and peripheral blood smear with hypersegmented neutrophils) and mild proteinuria (less than 0.5g/day) with absence of kidney function abnormality.

Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.


Dear Editor,
Imerslund-Grasbeck syndrome (IGS) is a rare autosomal recessive disorder characterized by megaloblastic anemia due to selective vitamin B<sub>12</sub> malabsorption and asymptomatic proteinuria. IGS occurs in the first 1-2 years of the life and megaloblastic anemia is responsive to parenteral vitamin B<sub>12</sub> treatment. It is thought that proteinuria is benign in IGS; however, there is no sufficient number of follow-up series in IGS.

Case report
A 22-year-old woman had been referred to our pediatric outpatient clinic with the complaints of pale skin, loss of appetite, ataxia and diarrhea constipation periods when she was 2-year-old. The clinical examination and laboratory studies revealed pallor of conjunctiva, megaloblastic anemia with vitamin B12 deficiency (serum vitamin B<sub>12</sub> level <150pg/ml, hemoglobin: 6.5g/dl, MCV: 104fl and peripheral blood smear with hypersegmented neutrophils) and mild proteinuria (less than 0.5g/day) with absence of kidney function abnormality.

Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.


Dear Editor,
Imerslund-Grasbeck syndrome (IGS) is a rare autosomal recessive disorder characterized by megaloblastic anemia due to selective vitamin B<sub>12</sub> malabsorption and asymptomatic proteinuria. IGS occurs in the first 1-2 years of the life and megaloblastic anemia is responsive to parenteral vitamin B<sub>12</sub> treatment. It is thought that proteinuria is benign in IGS; however, there is no sufficient number of follow-up series in IGS.

Case report
A 22-year-old woman had been referred to our pediatric outpatient clinic with the complaints of pale skin, loss of appetite, ataxia and diarrhea constipation periods when she was 2-year-old. The clinical examination and laboratory studies revealed pallor of conjunctiva, megaloblastic anemia with vitamin B12 deficiency (serum vitamin B<sub>12</sub> level <150pg/ml, hemoglobin: 6.5g/dl, MCV: 104fl and peripheral blood smear with hypersegmented neutrophils) and mild proteinuria (less than 0.5g/day) with absence of kidney function abnormality.

Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.

Two renal biopsies were performed because of persistent proteinuria, however, there was no remarkable histologically changes. She was diagnosed with IGS in the light of this clinical picture. Anemia and neurological symptoms were improved with vitamin B12 therapy in the next few weeks. Mild proteinuria remains persist with normal kidney function and she is being still followed-up with periodically for proteinuria.


Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.

Citations

Zafer Ercan¹, Mehmet E. Demir², Turgay Ulas³, Muharrem Ingeç⁴, Mehmet Horoz⁵
¹ Department of Nephrology, Yıldırım Beyazıt Training and Research Hospital. Ankara (Turkey).
² Department of Nephrology. Harran University, School of Medicine. Sanliurfa (Turkey).
³ Department of Internal Medicine. Harran University, School of Medicine. Sanliurfa (Turkey).
⁴ Department of Nephrology. Harran University, School of Medicine. Yenisehir campus. 63300 Sanliurfa, Turkey.
⁵ Corresponedence: Mehmet E. Demir. Department of Nephrology. Harran University, School of Medicine. 63300 Sanliurfa, Turkey.
demirmehmetem@hotmail.com

Reacción adversa por la administración intravenosa de hierro: ¿hipersensibilidad o efecto secundario?

Señor Director:

La reposición de hierro es necesaria en los pacientes de hemodiálisis debido a las pérdidas hemáticas crónicas que se producen con la técnica. La administración de hierro intravenoso (hierro dextramaltosa) se describe de forma aislada como poco frecuente (entre un 1/100-1000 de los pacientes); la tasa de efectos adversos relacionados con la administración de diversos preparados de hierro intravenoso (hierro dextrano de alto y bajo peso molecular, gluconato férrico, hierro sucroso) se sitúa en torno a 30 por millón⁴. El prurito asociado al hierro carboximaltosa se describe de forma aislada como poco frecuente (entre un 1/100-1000 de los pacientes)⁴;